AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer
AIkido Pharma Inc. (Nasdaq: AIKI) announced positive results from its Artificial Intelligence/Machine Learning research for pancreatic cancer. Pancreatic ductal adenocarcinoma (PDA) is the third leading cancer-related death cause in the US, with a low five-year survival rate of only 9%. AIkido's innovative approach involves screening drugs in primary cell culture and validating them in mouse models to discover effective treatments for early-stage PDA and post-surgical relapse prevention. The full article is available at Nature.com.
- Publication of promising results from AI/Machine Learning research targeted at pancreatic cancer.
- AIkido's unique approach emphasizes early-stage cancer treatment, potentially improving survival rates.
- Pancreatic ductal adenocarcinoma has a low five-year survival rate of just 9%, indicating the significant challenge in treatment.
- The need for effective therapies for late-stage PDA highlights a gap in current treatment options.
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related deaths in the US. PDA is increasing in frequency owing to its association with obesity, smoking, and type 2 diabetes. PDA treatment is severely compromised because most diagnoses are made late in disease progression. Surgical resection remains the most effective therapeutic strategy but is restricted to early stage diagnosis and is rarely, if ever, curative. In spite of the decades of research and recent advances, the five-year survival rate has only improved to
Thus, there is a pressing need for systematic and robust screens to develop novel, effective PDA therapeutics for early stage disease and after successful surgical resection to delay or prevent relapse. AIkido's strategy to identify better therapeutics is to screen drugs in primary cell culture, followed by validation in a mouse model of early disease progression.
The full article is available at: https://rdcu.be/cblR4 (See Nature.com Nov 26, 2020; Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact: | |
Investor Relations: | |
Hayden IR | |
Brett Maas, Managing Partner | |
Phone: (646) 536-7331 | |
Email: brett@haydenir.com | |
AIkido Pharma Inc.: | |
Phone: 212-745-1373 | |
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-publication-of-artificial-intelligence-machine-learning-sponsored-research-program-for-pancreatic-cancer-301189567.html
SOURCE AIkido Pharma Inc.
FAQ
What recent results did AIkido Pharma announce regarding pancreatic cancer?
What is the survival rate for pancreatic ductal adenocarcinoma according to AIkido Pharma's announcement?
How is AIkido Pharma approaching pancreatic cancer treatment development?
What is the significance of AIkido Pharma's recent publication?
What disease does AIkido Pharma's recent research focus on?
